Record overview
Status and phase
Status: RECRUITING
Phase: PHASE2
Sponsor: Daiichi Sankyo
Condition: Recurrent or Metastatic Solid Tumors
NCT06330064
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: large_enrollment_target_signal | rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.